leisure time -WSS

leisure time

author：leisure time 2025-10-02 18:47:24 - browse：8836

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Winners, losers from Medicare’s list of drugs subject to price talks

WSS

Drug firms test therapies to halt Alzheimer’s before symptoms arise

STAT readers on older presidents, polypills, Medicare, and more

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

NIH study of ME/CFS points to clear biological hallmarks

Ed Silverman on new gene therapies, biosimilars, coffee, and more

leisure time

leisure time

hotspot

What does generative AI mean for health care? We asked experts

2024 GOP presidential candidates spar over abortion in debate

Hepatitis C has a cure — but many Americans still lack access to it

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Apple is now the first public company to be valued at $3 trillion

He's a Nobel laureate. Critics say he was misleading on Covid

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Guidelines to prevent youth baseball injuries need more muscle

A new nitrogen execution bill also undermines medical licensing

hotspot

Alabama hospital puts IVF treatments on hold

A new nitrogen execution bill also undermines medical licensing

New documents shed light on MD Anderson Cancer Institute feud

Departing Stanford president retracts two papers

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

6 phony surgeries that take placebo to the extreme

hotspot

focus

explore

focus